
A meta-analysis of preclinical and clinical studies found significant reductions in male fertility parameters linked to Valproic acid (VPA) use in epilepsy patients. Preclinical results showed decreased sperm count (SMD = -2.28) and motility (SMD = -2.32), with a significant rise in abnormal sperm (SMD = 3.27). In clinical studies, VPA treatment led to a non-significant reduction in sperm count (SMD = -0.78) but significantly reduced sperm motility (SMD = -1.62). No significant changes were noted in FSH and LH levels. The analysis underscores the need for caution in prescribing VPA, particularly for young male epilepsy patients due to its potential adverse effects on reproductive health.
Like
Save
Share